PPARG and type 2 diabetes mellitus: Our previous studies have shown that Pio, a PPAR-γ agonist used in the treatment of type 2 diabetes, could protect against renal IRI by inhibiting renal cell apoptosis and exhibiting an antioxidant effect (Hu et al., 2012; Zou et al., 2013).